

CORRECTION

Correction: Targeting CENPN to inhibit breast cancer progression: insights into cell growth and aerobic glycolysis modulation

Zhe Ye¹, Qiuyan Lin², Hualong Lin², Yiwei Huang^{1,*}

¹Department of Tumor Radiotherapy, The Third Affiliated Hospital of Wenzhou Medical University, 325200 Rui'an, Zhejiang, China

²Department of Oncology, The Third Affiliated Hospital of Wenzhou Medical University, 325200 Rui'an, Zhejiang, China

***Correspondence**

yw_huang0711@163.com (Yiwei Huang)

The authors regret that two references were incorrectly cited in the original publication [1]. The correct references are as follows:

Reference 22 should be replaced with: Jafari-Oliayi A, Dabiri S. SNHG6 203 RNA may be involved in the cell cycle progression in HER2-negative breast cancer cells. *Iranian Journal of Pathology*. 2022; 17: 251–260.

Reference 25 should be replaced with: Li X, Tang L, Chen Q, Cheng X, Liu Y, Wang C, *et al.* Inhibition of MYC suppresses programmed cell death ligand-1 expression and

enhances immunotherapy in triple-negative breast cancer. *Chinese Medical Journal*. 2022; 135: 2436–2445.

The authors apologize for any inconvenience caused.

REFERENCES

- [1] Ye Z, Lin QY, Lin HL, Huang YW. Targeting CENPN to inhibit breast cancer progression: insights into cell growth and aerobic glycolysis modulation. *European Journal of Gynaecological Oncology*. 2024; 45: 147–157.